Roquefort Investments PLC Admission to Trading & First Day of Dealing (9396S)
March 22 2021 - 3:00AM
UK Regulatory
TIDMROQ
RNS Number : 9396S
Roquefort Investments PLC
22 March 2021
22 March 2021
roquefort investments PLC
("Roquefort Investments" or the "Company")
Admission to Trading & First Day of Dealings
Roquefort Investments plc, an investment company established to
acquire businesses focused on early stage opportunities in the
medical biotechnology sector, is pleased to announce that following
the publication of its prospectus on 17 March 2021, the admission
of the Company's entire issued share capital to the Official List
of the UKLA by way of a standard listing under Chapter 14 of the
UKLA's Listing Rules and to trading on the London Stock Exchange's
main market for listed securities.
The Company also completed a placing of 20,000,000 shares at 5p
per share raising a gross amount of GBP1 million.
Dealings will commence at 8.00 a.m. today under the TIDM "ROQ".
The Company's ISIN is GB00BMDQ2T15 and SEDOL number is BMDQ2T1.
The Prospectus is available to be viewed at the Company's
website at: www.roquefortinvest.com
Stephen West, Chairman of Roquefort Investments, commented: "The
team behind Roquefort Investments is delighted to be commencing
this journey as a listed business. We have a clear growth strategy
focused on an exciting market where we believe there are highly
compelling opportunities that will deliver value for our
shareholders, as well as value for the businesses that we
ultimately acquire. The funds raised will enable Roquefort
Investments to progress the formal screening of opportunities and
we look forward to providing details in due course when we find an
appropriate target to move on."
Enquiries:
Roquefort Investments plc
+44 (0)20 3290
Stephen West (Chairman) 9339
Optiva Securities Limited (Broker)
+44 (0)20 3411
Christian Dennis 1881
About Roquefort Investments
Roquefort Investments was formed as an investment company to
acquire businesses focused on early-stage opportunities in the
medical biotechnology sector with the aim of generating optimal
returns for both the target businesses and our shareholders. It is
envisaged that such acquisition or acquisitions will trigger a
reverse takeover in accordance with the listing rules.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
LISSEIFISEFSEDD
(END) Dow Jones Newswires
March 22, 2021 03:00 ET (07:00 GMT)
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From May 2024 to Jun 2024
Roquefort Therapeutics (LSE:ROQ)
Historical Stock Chart
From Jun 2023 to Jun 2024